Functional interactions of the cystine/glutamate antiporter, CD44V and MUC1-C oncoprotein in triple-negative breast cancer cells

Oncotarget

Volumn 7, Issue 11, 2016, Pages 11756-11769

  Hasegawa, Masanori ^a   Takahashi, Hidekazu ^a,b   Rajabi, Hasan ^a   Alam, Maroof ^a   Suzuki, Yozo ^a,c   Yin, Li ^a   Tagde, Ashujit ^a   Maeda, Takahiro ^a   Hiraki, Masayuki ^a   Sukhatme, Vikas P ^a   Kufe, Donald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

Author keywords

CD44v; Epigenetics; Ferroptosis; MUC1 C; xCT

Indexed keywords

AMINO ACID TRANSPORTER; CD44V ANTIGEN; ERASTIN; GLUTATHIONE; MUCIN 1; MUCIN 1 C PROTEIN; PROTEIN INHIBITOR; SYSTEM XC CYSTINE GLUTAMATE ANTIPORTER PROTEIN; UNCLASSIFIED DRUG; CD44 PROTEIN, HUMAN; CYSTINE; GLUTAMIC ACID; HYALURONIC ACID BINDING PROTEIN; MUC1 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; SLC7A11 PROTEIN, HUMAN;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENETIC TRANSCRIPTION; HISTONE METHYLATION; MUC1 GENE; MUCIN 1 GENE; PROMOTER REGION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; TRIPLE NEGATIVE BREAST CANCER; AMINO ACID SEQUENCE; CELL PROLIFERATION; FEMALE; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; TUMOR CELL CULTURE;

AMINO ACID SEQUENCE; AMINO ACID TRANSPORT SYSTEM Y+; CELL PROLIFERATION; CYSTINE; FEMALE; GLUTAMIC ACID; HUMANS; HYALURONAN RECEPTORS; MUCIN-1; OXIDATION-REDUCTION; PROMOTER REGIONS, GENETIC; REACTIVE OXYGEN SPECIES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84962909319     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7598     Document Type: Article

References (43)

1. Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, Massie A, Smolders I, Methner A, Pergande M, Smith SB, Ganapathy V and Maher P. The cystine/glutamate antiporter system Xc- in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013; 18:522-555.
2. Tagde A, Singh H, Kang MH and Reynolds CP. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Blood Cancer J. 2014; 4:e229.
3. Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K, Moriguchi T, Takahashi S and Bannai S. Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem. 2005; 280:37423-37429.
4. Huang L, Chen D, Liu D, Yin L, Kharbanda S and Kufe D. MUC1 oncoprotein blocks GSK3β-mediated phosphorylation and degradation of β-catenin. Cancer Res. 2005; 65:10413-10422.
5. Lo M, Wang YZ and Gout PW. The Xc- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008; 215:593-602.
6. Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, Guo XL, Dong LJ, He X, Qiao HX, Zhan QM and Li W. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene. 2009; 28:599-609.
7. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system Xc-and thereby promotes tumor growth. Cancer Cell. 2011; 19:387-400.
8. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F and Gray JW. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013; 24:450-465.
9. Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen I, Bullen JW and Semenza GL. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci USA. 2015; 112:E4600-9.
10. Okuno S, Sato H, Kuriyama-Matsumura K, Tamba M, Wang H, Sohda S, Hamada H, Yoshikawa H, Kondo T and Bannai S. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer. 2003; 88:951-956.
11. Narang VS, Pauletti GM, Gout PW, Buckley DJ and Buckley AR. Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy. 2007; 53:210-217.
12. Kufe D. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013; 32:1073-1081.
13. Siroy A, Abdul-Karim FW, Miedler J, Fong N, Fu P, Gilmore H and Baar J. MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. Hum Pathol. 2013; 44:2159-2166.
14. Bieche I and Lidereau R. A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors. Cancer Genet Cytogenet. 1997; 98:75-80.
15. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV and Abba MC. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet. 2010; 201:102-110.
16. Khodarev N, Pitroda S, Beckett M, MacDermed D, Huang L, Kufe D and Weichselbaum R. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009; 69:2833-2837.
17. Raina D, Ahmad R, Joshi M, Yin L, Wu Z, Kawano T, Vasir B, Avigan D, Kharbanda S and Kufe D. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009; 69:5133-5141.
18. Ahmad R, Rajabi H, Kosugi M, Joshi M, Alam M, Vasir B, Kawano T, Kharbanda S and Kufe D. MUC1-C oncoprotein promotes STAT3 activation in an auto-inductive regulatory loop. Sci Signal. 2011; 4:ra9.
19. Yamada N, Nishida Y, Tsutsumida H, Hamada T, Goto M, Higashi M, Nomoto M and Yonezawa S. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res. 2008; 68:2708-2716.
20. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S and Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell. 2007; 27:992-1004.
21. Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J and Kufe D. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene. 2014; 33:3422-3431.
22. Raina D, Agarwal P, Lee J, Bharti A, McKnight C, Sharma P, Kharbanda S and Kufe D. Characterization of the MUC1-C cytoplasmic domain as a cancer target. PLoS One. 2015; 10:e0135156.
23. Kufe D. Mucins in cancer: function, prognosis and therapy. Nature Reviews Cancer. 2009; 9:874-885.
24. Alam M, Rajabi H, Ahmad R, Jin C and Kufe D. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget. 2014; 5:2622-2634. doi: 10.18632/oncotarget.1848.
25. Hensley CT, Wasti AT and DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013; 123:3678-3684.
26. Nagano O, Okazaki S and Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 2013; 32:5191-5198.
27. Hitchler MJ and Domann FE. Metabolic defects provide a spark for the epigenetic switch in cancer. Free Radic Biol Med. 2009; 47:115-127.
28. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, 3rd and Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149:1060-1072.
29. Dyson HJ and Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol. 2005; 6:197-208.
30. Tanabe KK, Ellis LM and Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet. 1993; 341:725-726.
31. Yan Y, Zuo X and Wei D. Concise Review: Emerging role of CD44 in cancer stem cells: A promising biomarker and therapeutic target. Stem cells translational medicine. 2015; 4:1033-1043.
32. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S and Kufe D. MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signaling. Nat Cell Biol. 2007; 9:1419-1427.
33. Ahmad R, Raina D, Joshi MD, Kawano T, Kharbanda S and Kufe D. MUC1-C oncoprotein functions as a direct activator of the NF-κB p65 transcription factor. Cancer Res. 2009; 69:7013-7021.
34. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C, Joshi MD, MacDermed D, Weichselbaum R and Kufe D. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 2010; 29:920-929.
35. Joshi MD, Ahmad R, Raina D, Rajabi H, Bubley G, Kharbanda S and Kufe D. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther. 2009; 8:3056-3065.
36. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro G, Supko J, Kharbanda S and Kufe D. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Therapeutics. 2011; 10:806-816.
37. Jin C, Rajabi H, Pitroda S, Kharbanda A, Li A, Weichselbaum R and Kufe D. Cooperative interaction between the MUC1 oncoprotein and the Rab31 GTPase in human breast cancer cells. PLoS One 2012; 7:e39432
38. Hasegawa M, Sinha RK, Kumar M, Alam M, Yin L, Raina D, Kharbanda A, Panchamoorthy G, Gupta D, Singh H, Kharbanda S and Kufe D. Intracellular targeting of the oncogenic MUC1-C protein with a novel GO-203 nanoparticle formulation. Clin Cancer Res. 2015; 21:2338-2347.
39. Panchamoorthy G, Rehan H, Kharbanda A, Ahmad R and Kufe D. A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain. Hybridoma. 2011; 30:531-535.
40. Rajabi H, Ahmad R, Jin C, Kosugi M, Alam M, Joshi M and Kufe D. MUC1-C oncoprotein induces TCF7L2 activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem. 2012; 287:10703-10713.
41. Takahashi H, Jin C, Rajabi H, Pitroda S, Alam M, Ahmad R, Raina D, Hasegawa M, Suzuki Y, Tagde A, Bronson RT, Weichselbaum R and Kufe D. MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene. 2015; 34:5187-97.
42. Alam M, Ahmad R, Rajabi H, Kharbanda A and Kufe D. MUC1-C oncoprotein activates ERK→C/EBPβ-mediated induction of aldehyde dehydrogenase activity in breast cancer cells. J Biol Chem. 2013; 288:30829-30903.
43. Wang Q, Carroll JS and Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell. 2005; 19:631-642.